The positive news from the clinical trial is directly related to Allarity Therapeutics' core business and future revenue potential, which typically leads to increased investor confidence and a rise in stock price. Given the significance of successful Phase 2 trial results in the biotech industry, especially for treatments of severe conditions like advanced ovarian cancer, this news is likely to have a strong positive impact on the stock in the short term.